Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Other EventsItem 8.01 · 8-KMEDIUM RiskNegative

Alzamend Neuro, Inc.

Filed: Jul 21, 2026CIK: 0001677077
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Dr. Lynne Fahey McGrath, a board director since Alzamend Neuro's June 2021 IPO, passed away on July 20, 2026. This represents a loss of experienced biopharmaceutical sector expertise and strategic guidance for the emerging growth company.

Key Takeaways

Dr. Lynne Fahey McGrath, who served as a director since the company's IPO in June 2021, passed away on July 20, 2026

Chairman William B. Horne emphasized Dr. McGrath's significant contributions to the company's strategy and governance

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 21, 2026
Item8.01
CategoryOther Events
CIK0001677077
Risk LevelMEDIUM
SentimentNegative
Signalinformational
Topics
board changeleadership transition

What This Means

Other material events not covered by specific item numbers. The content of the filing determines significance.
View Full Filing on SEC.govBrowse More Filings